Síguenos en Twitter       Síguenos en Facebook       Síguenos en YouTube       Siguenos en Linkedin       Correo Grupsagessa       Gmail       Yahoo Mail       Dropbox       Instagram       Pinterest       Slack       Google Drive       Print       StumbleUpon

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

Buscar en contenido

Contenido:

martes, 12 de mayo de 2015

Morfina y antiagregantes plaquetarios

of action of antiplatelet agents.
MEDEST Mag 11, 2015 

"A recently published article entitled “Chest pain relief in patients with acute myocardial infarction” (European Heart Journal: Acute Cardiovascular Care April 22, 2015) address in a very well documentrd way the topic about drug-to-drug interaction between morfine and antiplatelets agents in STEMI patients...
As indicated in the article recent literature indicates an increased risk of mortality in STEMI patients treated with Morphine...
Given the key importance of platelet inhibition in patients treated by PPCI for STEMI and the absence of data that may support a potential clinical benefit of morphine in patients with acute myocardial infarction, more caution should be used regarding morphine administration in STEMI patients, and a restricted morphine use seems to be reasonably recommended...
Bottom Line
  • The first impact to reduce chest pain has to be reserved to Nitrates or B-blockers (where all contraindications are excluded).
  • After this NRS has to be evaluated and the use of Morphine is indicated only for values above 7. For lower values Paracetamol or Aspirin are the agents of choice."
Courtesely from Dott. Guido Parodi
http://medest118.com/2015/05/11/drug-to-drug-interaction-new-evidences-on-morphine-and-delayed-onset-of-action-of-antiplatelet-agents/